Article
11 Dec 2024
Biosimilar Updates: EYLEA® IPR Filings, Herceptin® Biosimilar Hercessi™ Launch, Stelara® Biosimilar Yesintek™ Approval
AUTHORS CONTENT
Article
21 Nov 2024
BPCIA Lawsuit Against Accord's Proposed Prolia® / Xgeva® Biosimilar Filed By Amgen
Article
18 Nov 2024
Amgen Launches Pavblu™ As The First EYLEA® Biosimilar In The U.S.
Article
07 Nov 2024
FDA Accepts ABLAs For Prolia® / Xgeva® Biosimilars From Organon And Teva
Article
28 Oct 2024
Amgen Plans At-Risk Launch Of EYLEA® Biosimilar Pavblu™ After Federal Circuit Lifts Temporary Injunction
Article
22 Oct 2024
Accord BioPharma's Stelara® Biosimilar Imuldosa™ Approved By FDA
Article
15 Oct 2024
PTAB Grants Institution Of Eight IPRs Challenging The Johns Hopkins University Pembrolizumab Patents
Article
15 Oct 2024
Amgen Files Fourth BPCIA Lawsuit Against Proposed Prolia® / Xgeva® Biosimilar – Fresenius Kabi's FKS518
Article
03 Oct 2024
Fresenius Kabi And Formycon Announce Approval Of Stelara® Biosimilar Otulfi™ In The U.S. And E.U.
Article
27 Sep 2024
Preliminary Injunction Against Amgen's EYLEA® Biosimilar Pavblu™ Denied
Article
05 Jul 2024
FDA Approves Three Biosimilars – Ahzantive® (Aflibercept-mrbb), Nypozi™ (Filgrastim-txid), And Pyzchiva® (Ustekinumab-ttwe)
Article
03 Jul 2024
PTAB Issues Final Written Decision Invalidating Regeneron's EYLEA® Patent (IPR2023-00442)
Article
01 Jul 2024
FDA Revises Guidance On Switching Studies For Biosimilar Interchangeability
Article
27 Jun 2024
PTAB Grants Institution Of IPR Challenging The Johns Hopkins University Pembrolizumab Patent
Article
19 Jun 2024
Permanent Injunction Issued Preventing Launch Of EYLEA® Biosimilar Yesafili™
Article
05 Jun 2024
FDA Approves First Interchangeable Biosimilar Of Alexion's Soliris® (Eculizumab) – Amgen's Bkemv™ (Eculizumab-Aeeb)
Article
05 Jun 2024
Amgen Files BPCIA Lawsuit Against Celltrion's Proposed Prolia® / Xgeva® (Denosumab) Biosimilar CT-P41
Article
31 May 2024
Fresenius Kabi Announces FDA Acceptance Of ABLA For Prolia® / Xgeva® (Denosumab) Biosimilar Candidate FKS518
Article
29 May 2024
Regeneron Files Second BPCIA Complaint Against Celltrion's Proposed EYLEA® Biosimilar CT-P42
Article
27 May 2024
The First Biosimilar Disputes At The Unified Patent Court (UPC)